At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 580 enrolled
Drug / intervention
levocetirizine dihydrochloride +1 moredrug
Likely dose
levocetirizine dihydrochloride 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis
In Brief
A Phase 4 clinical trial evaluating levocetirizine dihydrochloride and placebo for Seasonal Allergic Rhinitis. Completed, enrolled 580 participants across 38 sites.
Detailed Summary
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionJul 2008
TodayJul 2026
First PostedApr 4, 2008
Enrollment StartApr 1, 2008
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.2 years ago
Interventions
levocetirizine dihydrochloridedrug
5 mg daily (oral tablet) for 14 days
placebodrug
0 mg daily (matching oral tablet) for 14 days